Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2335175 | 1.00 | MAPT (0.47) | MAPTTDP1CYP2C9CYP2C19POLB | |
| SCHEMBL14848764 | 0.93 | MAPT (0.44) | MAPTTDP1CYP2C9CYP2C19POLB | |
| SCHEMBL18615601 | 0.87 | MAPT (0.48) | MAPTTDP1CYP2C9CYP2C19POLB | |
| SCHEMBL18615597 | 0.87 | MAPT (0.48) | MAPTTDP1CYP2C9CYP2C19POLB | |
| SCHEMBL18615671 | 0.87 | MAPT (0.48) | MAPTTDP1CYP2C9CYP2C19POLB | |
| SCHEMBL29116484 | 0.84 | USP30 (0.45) | MAPTTDP1STSPIK3CDTACR1 | |
| SCHEMBL31233745 | 0.84 | USP30 (0.45) | MAPTTDP1STSPIK3CDTACR1 | |
| SCHEMBL27077000 | 0.84 | USP30 (0.45) | MAPTTDP1STSPIK3CDTACR1 | |
| SCHEMBL2339872 | 0.83 | STS (0.51) | STSPIK3CDTACR1PIK3CAUSP30 | |
| SCHEMBL2339564 | 0.83 | STS (0.51) | STSPIK3CDTACR1PIK3CAUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975262-B2 | Synthetic mimetics of host defense and uses thereof | CELLCEUTIX CORPORATION (US) | 2015-03-10 | — | — | US | claimed |
| US-20130090345-A1 | Synthetic Mimetics Of Host Defense And Uses Thereof | POLYMEDIX, INC. (US) | 2013-04-11 | — | — | US | claimed |
| US-8278309-B2 | Synthetic mimetics of host defense and uses thereof | POLYMEDIX, INC. (US) | 2012-10-02 | — | — | US | claimed |
| EP-2358380-A1 | SYNTHETIC MIMETICS OF HOST DEFENSE AND USES THEREOF | Polymedix, Inc. (US) | 2011-08-24 | — | — | EP | claimed |
| WO-2010062573-A1 | SYNTHETIC MIMETICS OF HOST DEFENSE AND USES THEREOF | POLYMEDIX, INC. (US) | 2010-06-03 | — | — | WO | claimed |
| US-20100105703-A1 | Synthetic Mimetics Of Host Defense And Uses Thereof | POLYMEDIX, INC. (US) | 2010-04-29 | — | — | US | claimed |
| US-20230310435-A1 | HOST DEFENSE PROTEIN (HDP) MIMETICS FOR PROPHYLAXIS AND/OR TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT | INNOVATION PHARMACEUTICALS INC. (US) | 2023-10-05 | — | — | US | disclosed |
| EP-3258927-B1 | HOST DEFENSE PROTEIN (HDP) MIMETICS FOR PROPHYLAXIS AND/OR TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT | INNOVATION PHARMACEUTICALS INC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20160243117-A1 | Host Defense Protein (HDP) Mimetics For Prophylaxis And/Or Treatment Of Inflammatory Diseases Of The Gastrointestinal Tract | CELLCEUTIX CORPORATION (US) | 2016-08-25 | — | — | US | disclosed |
| US-8975262-B2 | Synthetic mimetics of host defense and uses thereof | CELLCEUTIX CORPORATION (US) | 2015-03-10 | — | — | US | disclosed |
| CN-102256614-B | Synthetic mimetics of host defense and uses thereof | POLYMEDIX INC | 2014-01-08 | — | — | CN | disclosed |
| US-20130090345-A1 | Synthetic Mimetics Of Host Defense And Uses Thereof | POLYMEDIX, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-8278309-B2 | Synthetic mimetics of host defense and uses thereof | POLYMEDIX, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2358380-A1 | SYNTHETIC MIMETICS OF HOST DEFENSE AND USES THEREOF | Polymedix, Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010062573-A1 | SYNTHETIC MIMETICS OF HOST DEFENSE AND USES THEREOF | POLYMEDIX, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100105703-A1 | Synthetic Mimetics Of Host Defense And Uses Thereof | POLYMEDIX, INC. (US) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090345-A1 | Synthetic Mimetics Of Host Defense And Uses Thereof | TLR3, MYD88, TLR5 | MAPT 4705/4885TDP1 4134/4885CYP2C9 4158/4885 |
| US-20160243117-A1 | Host Defense Protein (HDP) Mimetics For Prophylaxis And/Or Treatment Of Inflammatory Diseases Of The Gastrointestinal Tract | FABP2, HMGB1, MASP2 | MAPT 4232/4885TDP1 3674/4885CYP2C9 4692/4885 |
| US-20100105703-A1 | Synthetic Mimetics Of Host Defense And Uses Thereof | TLR3, MYD88, TLR5 | MAPT 4705/4885TDP1 4134/4885CYP2C9 4158/4885 |
| US-20230310435-A1 | HOST DEFENSE PROTEIN (HDP) MIMETICS FOR PROPHYLAXIS AND/OR TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT | FABP2, HMGB1, MASP2 | MAPT 4232/4885TDP1 3674/4885CYP2C9 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.